HIF-1α Ameliorates Diabetic Neuropathic Pain via Parkin-Mediated Mitophagy in a Mouse Model. (16th August 2022)

• Record Type: Journal Article
• Authors: He, Jian; Qin, Zaisheng; Chen, Xin; He, Wanyou; Li, Donglin; Zhang, Lei; Le, Yue; Xiong, Qingming; Zhang, Bin; Wang, Hanbing
• Other Names: Ahmad Saheem Academic Editor.
• Is Part Of: BioMed research international. Volume 2022(2022)
• Publication Date: 2022-08-16
• Subjects: Medicine -- Periodicals; Biology -- Periodicals; Biotechnology -- Periodicals; Life sciences -- Periodicals; 610.5
• DOI: 10.1155/2022/5274375
• Languages: English
• ISSNs: 2314-6133

Abstract

Abstract : Mitochondrial dysfunction, which can be regulated by mitophagy, plays a central role in diabetic neuropathic pain (DNP). Mitophagy that was involved in nerve damage-induced neuropathic pain has been reported. Hyperglycemia and cellular hypoxic were the two main characters of diabetes. Hypoxia-inducible factor 1 α subunit (HIF-1 α ) plays a vital role in mitochondrial homeostasis under hypoxia. However, it remains unclear whether mitophagy was changed and could be regulated by HIF-1 α in DNP. In this study, the results showed that mitophagy was activated and HIF-1 α was upregulated in the spinal cord of diabetic mice. HIF-1 α agonist dimethyloxalylglycine (DMOG) could further elevate HIF-1 α and Parkin protein, enhance mitophagy, decrease mitochondrial dysfunction, and hyperalgesia. Furthermore, Park2 (encoding Parkin) knockout aggravated hyperalgesia and mitochondrial dysfunction in diabetic mice. Furthermore, mitophagy could not be activated and induced by HIF-1 α agonist DMOG in Park2 -/- diabetic mice. In this study, we first demonstrated that HIF-1 α could upregulate mitophagy in the spinal cord of mice with DNP through modulating the Parkin signaling pathway, promoting new insights into the mechanisms and research of treatment strategies for patients with DNP.